Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on March 4, 2019, reporting an event that occurred on March 1, 2019. The company is incorporated in Delaware and is headquartered in San Diego, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a corporate governance amendment and does not contain financial performance data.
Material Changes
On March 1, 2019, the Company filed Amendment No. 2 to its Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock with the Delaware Secretary of State. The amendment corrected the par value of the Series C Convertible Preferred Stock to $0.001 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the stock certificate amendment.
Investor Verification Checklist
- Verify the corrected par value of $0.001 per share for Series C Convertible Preferred Stock.
- Confirm the filing of Amendment No. 2 with the Delaware Secretary of State.
- Note that this filing contains no financial results or operational updates.